Comparison of Survivin Determination by Surface-Enhanced Fluorescence and Raman Spectroscopy on Nanostructured Silver Substrates.


Journal

Biosensors
ISSN: 2079-6374
Titre abrégé: Biosensors (Basel)
Pays: Switzerland
ID NLM: 101609191

Informations de publication

Date de publication:
06 Oct 2024
Historique:
received: 29 07 2024
revised: 26 09 2024
accepted: 01 10 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

Survivin belongs to a family of proteins that promote cellular proliferation and inhibit cellular apoptosis. Its overexpression in various cancer types has led to its recognition as an important marker for cancer diagnosis and treatment. In this work, we compare two approaches for the immunochemical detection of survivin through surface-enhanced fluorescence or Raman spectroscopy using surfaces with nanowires decorated with silver nanoparticles in the form of dendrites or aggregates as immunoassays substrates. In both substrates, a two-step non-competitive immunoassay was developed using a pair of specific monoclonal antibodies, one for detection and the other for capture. The detection antibody was biotinylated and combined with streptavidin labeled with rhodamine for the detection of surface-enhanced fluorescence, while, for the detection via Raman spectroscopy, streptavidin labeled with peroxidase was used and the signal was obtained after the application of 3,3',5,5'-tetramethylbenzidine (TMB) precipitating substrate. It was found that the substrate with the silver dendrites provided higher fluorescence signal intensity compared to the substrate with the silver aggregates, while the opposite was observed for the Raman signal. Thus, the best substrate was used for each detection method. A detection limit of 12.5 pg/mL was achieved with both detection approaches along with a linear dynamic range up to 500 pg/mL, enabling survivin determination in human serum samples from both healthy and ovarian cancer patients for cancer diagnosis and monitoring purposes.

Identifiants

pubmed: 39451692
pii: bios14100479
doi: 10.3390/bios14100479
pii:
doi:

Substances chimiques

Silver 3M4G523W1G
Survivin 0
BIRC5 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : the European Regional Development Fund of the European Union and Greek national funds
ID : Τ2ΕΔΚ-03746 BioNanoDiagnostiki

Auteurs

Georgia Geka (G)

Immunoassays/Immunosensors Laboratory Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.
Department of Chemistry, National and Kapodistrian University of Athens, University Campus, 15771 Athens, Greece.

Anastasia Kanioura (A)

Immunoassays/Immunosensors Laboratory Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.

Ioannis Kochylas (I)

Section of Condensed Matter Physics, Department of Physics, National and Kapodistrian University of Athens, University Campus, 15784 Athens, Greece.

Vlassis Likodimos (V)

Section of Condensed Matter Physics, Department of Physics, National and Kapodistrian University of Athens, University Campus, 15784 Athens, Greece.

Spiros Gardelis (S)

Section of Condensed Matter Physics, Department of Physics, National and Kapodistrian University of Athens, University Campus, 15784 Athens, Greece.

Anastasios Dimitriou (A)

Institute of Nanoscience & Nanotechnology, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.

Nikolaos Papanikolaou (N)

Institute of Nanoscience & Nanotechnology, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.

Anastasios Economou (A)

Department of Chemistry, National and Kapodistrian University of Athens, University Campus, 15771 Athens, Greece.

Sotirios Kakabakos (S)

Immunoassays/Immunosensors Laboratory Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.

Panagiota Petrou (P)

Immunoassays/Immunosensors Laboratory Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, NCSR "Demokritos", 15341 Aghia Paraskevi, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH